Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.
Follow TNDM
Tandem Diabetes Care, Inc. (TNDM) P/E ratio
Tandem Diabetes Care, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 1,368× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 627× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PRCT PROCEPT BioRobotics Corporation compare | n/m |
| AORT Artivion, Inc. compare | n/m |
| CBLL CeriBell, Inc. compare | n/m |
| IART Integra LifeSciences Holdings Corporation compare | n/m |
| LMRI Lumexa Imaging Holdings, Inc. compare | n/m |
| ENOV Enovis Corporation compare | n/m |
| TNDM Tandem Diabetes Care, Inc. | n/m |
| BVS Bioventus Inc. compare | 16.4× |
| IRMD iRadimed Corporation compare | 48.5× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)